Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-06-11

Clinical Trial Update: Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging trial of Adcetris (brentuximab vedotin) in adults with systemic lupus erythematosus was terminated; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Adcetris (Brentuximab vedotin)

Snippet

Sponsor: Seagen Inc. | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: TERMINATED | Results posted: 2018-06-11